Aberrations in cell signaling, often resulting from mutations or overexpression of signal transduction proteins, are responsible for a host of diseases including cancer and inflammatory and metabolic diseases. Many drug targets, like kinases, are involved in signal transduction. While it has been relatively easy to develop biochemically potent compounds the translation of these compounds into efficacious drugs in more complex biological models remains a challenge. Part of the reason for this is the complexity in cellular signaling itself. Although, there has been a basic understanding of basic signaling pathways for decades, it is only recently that we have come to appreciate that the redundancy, cross-talk, and feedback in these pathways presents an obstacle to drug discovery. Examples highlighting the importance of signaling on cellular drug activity, along with a case study comparing biochemical activities and cellular activities of clinical kinase inhibitors are presented in this webinar. |
|